Boston, US – At the Extra-Hepatic LNP Delivery Summit in Boston, Pierre Dönnes, Co-Founder of Strike Pharma, presented the company’s work on adaptable antibody-based technologies for targeted lipid nanoparticle (LNP) delivery.